Lion's Mane and Cognitive Function: What the Research Shows

Lion's Mane and Cognitive Function

16 weeks of lion's mane improved cognitive scores in MCI patients; scores regressed within 4 weeks of stopping

Mori and colleagues' 2009 double-blind placebo-controlled trial remains the landmark clinical study for lion's mane and cognition. Significant improvement was documented at weeks 8, 12, and 16. Four weeks after the intervention ended, scores declined again, establishing that effects require continued use.

Mori et al., Phytotherapy Research, 2009

3 populations

with different evidence: MCI patients (strongest evidence, 3 positive RCTs), healthy young adults (task-specific effects), early Alzheimer's patients (1 pilot trial with positive findings)

Null result

Surendran et al. (2025) found that a single acute dose of lion's mane did not produce significant global cognitive improvement in healthy young adults, providing important nuance for healthy-adult users

Most reliable in impaired

Cha et al.'s 2024 systematic review concluded that lion's mane cognitive benefits are most consistent in cognitively impaired populations; effects in healthy populations are more variable and task-specific

Mori et al., Phytotherapy Research, 2009

View as image ↗

The Mori 2009 trial showed significant cognitive improvement in mild cognitive impairment patients over 16 weeks. The data point that receives almost no attention from the supplement industry: four weeks after the trial ended and participants stopped taking lion's mane, cognitive scores began declining back toward pre-trial levels. The improvement was real. It was also dependent on continued use.

This is the kind of honest finding that makes the evidence more credible, not less. A compound that produces genuine biological effects on a process that requires ongoing support will show regression when that support is removed. It tells you something about how lion's mane works. For the complete overview of what lion's mane is and does, see what is lion's mane mushroom: a science-based overview.

Key Takeaways

Mori et al. (2009) found significant cognitive function score improvement in 30 MCI patients at weeks 8, 12, and 16 of lion's mane versus placebo; scores declined within 4 weeks of stopping, indicating effects require ongoing supplementation
Saitsu and colleagues (2019) replicated the MCI finding in a different Japanese population using oral intake of H. erinaceus, confirming cognitive improvement with the same directional result
Li and colleagues (2020) conducted a pilot double-blind placebo-controlled study in early Alzheimer's patients using erinacine A-enriched mycelium; the positive findings extended the evidence from MCI to diagnosed early AD
Docherty and colleagues (2023) found lion's mane produced acute Stroop performance improvements and chronic stress/mood benefits in healthy young adults, though the cognitive effects were more task-specific than the MCI population improvements
Surendran and colleagues (2025) found that a single acute dose did NOT produce significant global cognitive improvement in healthy young adults, providing an important honest counterpoint to promotional content claiming immediate effects
Cha and colleagues' 2024 systematic review in Neuroscience and Biobehavioral Reviews concluded that cognitive benefits are most reliable in cognitively impaired populations; effects in healthy, unimpaired people are more variable and task-specific

The Mori 2009 RCT: The Landmark Trial and Its Overlooked Finding

Mori and colleagues (2009) published the foundational human clinical trial on lion's mane and cognitive function in Phytotherapy Research.^[1]

The design: 30 Japanese adults with diagnosed mild cognitive impairment (MCI), randomized to H. erinaceus tablets (providing approximately 750mg of dried mushroom equivalent) or placebo daily for 16 weeks. Cognitive assessment used the Hasegawa Dementia Scale, a validated tool for tracking cognitive change in elderly and MCI populations.

The primary result: the lion's mane group showed statistically significant improvement in cognitive function scores compared to the placebo group at weeks 8, 12, and 16. The effect was not subtle; the difference was consistent and grew over the treatment period, consistent with a mechanism that builds over weeks (NGF-driven neuroplasticity takes time).

The finding that most coverage omits: at a four-week follow-up assessment after participants stopped taking lion's mane, scores had begun declining toward pre-treatment levels. The improvement was not permanent. It was dependent on continued supplementation.

This regression finding is scientifically useful information. It confirms the cognitive improvement was not a statistical artifact. Real improvements that reverse when the intervention is removed demonstrate genuine mechanism-dependence. It also tells users what to expect: lion's mane supports a biological process (neuroplasticity) that requires ongoing support rather than one-time correction.

Saitsu 2019 and Li 2020: Two Replications That Narrow the Target

Mori's 2009 trial established proof of concept. Two subsequent trials provided replication.

Saitsu and colleagues (2019) tested oral intake of H. erinaceus in a Japanese population with subjective cognitive concerns, finding improvement in cognitive function scores in the treatment group.^[2] Different population, different formulation, consistent directional finding.

Li and colleagues (2020) conducted a pilot double-blind placebo-controlled study specifically in early Alzheimer's disease patients, using erinacine A-enriched mycelium (a more concentrated preparation of the specific compound class most implicated in the neuroprotective effects).^[4] The pilot found positive outcomes on cognitive and activities of daily living measures, extending the evidence from MCI into diagnosed AD patients. This is a pilot study, meaning it was designed to establish feasibility and preliminary signals rather than definitive efficacy.

Taken together, Mori 2009, Saitsu 2019, and Li 2020 establish a consistent pattern: lion's mane produces cognitive improvements in people with existing cognitive impairment, ranging from MCI to early AD. These are not tiny effects in tiny trials that happened to reach significance once; they are directionally consistent across three separate studies, populations, and formulations. For the specific evidence on lion's mane and memory, see can lion's mane improve memory: evidence from human and animal studies.

Healthy Young Adults: What Docherty 2023 Found

The MCI and early AD evidence is compelling. But the population most likely to be taking lion's mane supplements is healthy younger adults with no cognitive impairment, who represent the bulk of the nootropic market. The evidence for this population is different.

Docherty and colleagues (2023) tested lion's mane in a double-blind, parallel-groups pilot study in healthy young adults aged 18-45.^[3]

The findings were more nuanced than the MCI data. Acute effects: a single dose improved performance on the Stroop task, a measure of executive function and processing speed, at 60 minutes post-dose. This acute improvement represents a faster-acting mechanism than NGF-driven neuroplasticity. Chronic effects at 28 days: cognitive function improved alongside stress and mood measures, but the cognitive improvements were smaller in magnitude than those seen in MCI trials and appeared more selective.

This is the honest picture for healthy young adult users: some cognitive benefit exists, it appears task-specific rather than globally transformative, and the effect is more modest than what cognitively impaired populations experience. The therapeutic gap explains this: a brain with MCI has more structural deficit for NGF-driven neuroplasticity to address. A healthy brain has less room for measurable improvement.

The Null Result: Why Surendran 2025 Is as Important as Mori 2009

Supplement brands never publish the null results. The Surendran 2025 finding is a null result from a well-designed study, and it belongs in any honest review of lion's mane cognitive evidence.

Surendran and colleagues (2025) conducted a double-blind randomized placebo-controlled study specifically testing the acute effects of a standardized H. erinaceus extract in healthy younger adults.^[7] The finding on global cognitive function: no significant improvement from the acute dose.

This contrasts with Docherty 2023's Stroop finding. The difference likely reflects which specific cognitive tests were used, which formulations, and which dose levels. Not every measure shows benefit, and not every acute dose produces detectable cognitive change in healthy adults.

The null result is important because it corrects the inflated expectations that supplement marketing creates. Lion's mane is not like caffeine: you cannot expect to feel sharper 60 minutes after taking it. The evidence for acute effects is task-specific and inconsistent across formulations. The evidence for chronic effects in MCI patients is strong and replicable. Healthy adult users should expect more modest and more delayed effects.

What the 2024 Systematic Review Concludes

Cha and colleagues (2024) published a systematic review in Neuroscience and Biobehavioral Reviews examining mushroom effects on mood and neurocognitive health across the lifespan, including an analysis of all available lion's mane cognitive trials.^[5]

The conclusion most directly relevant to how lion's mane should be discussed: cognitive benefits are most reliable in cognitively impaired populations. In healthy, unimpaired people, effects are more variable and tend to be task-specific rather than broadly improving.

This is the synthesis that competitor content never provides. It is not that lion's mane only works in sick people. It is that the evidence is strong in cognitively impaired populations and considerably more mixed in healthy populations. A healthy 35-year-old and a 70-year-old with MCI are not the same population, and the evidence should not be presented as if they are.

Brandalise and colleagues (2023) conducted a comprehensive review of H. erinaceus in neurodegenerative diseases, examining the gap between bench (preclinical) and bedside (clinical) evidence, with similar conclusions about where the clinical evidence is and is not yet established.^[8]

What Lion's Mane Does to the Brain

The mechanism behind the cognitive improvements involves nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). These are proteins that support neuron survival, new connection formation, and hippocampal neurogenesis.

Erinacines from the mycelium cross the blood-brain barrier directly and stimulate glial cells to produce more NGF. Hericenones from the fruiting body activate a pan-neurotrophic pathway via ERK1/2 signaling that increases NGF, BDNF, and NT-3 simultaneously. The NGF and BDNF upregulation drives hippocampal neurogenesis over weeks of treatment, producing the structural changes that translate to measurable cognitive improvements.

This mechanism explains both the clinical pattern and the regression finding. The cognitive benefits in MCI trials are neurogenesis-dependent (Chong 2021 confirmed this causally): building and maintaining new hippocampal connections takes weeks of continued NGF support. When the support is removed, the process that was building those connections slows, and the cognitive scores decline as the underlying structure reverts.

Dose and Timeline: What the Trials Used

Across the published trials:

Mori 2009: approximately 750mg of dried H. erinaceus tablet daily for 16 weeks
Saitsu 2019: similar oral intake approach with H. erinaceus preparation
Li 2020: erinacine A-enriched mycelium at higher erinacine concentration for early AD population
Docherty 2023: standardized extract at 1.8g for healthy young adults
Surendran 2025: standardized extract acute dose in healthy adults

The consistent theme: meaningful cognitive effects in impaired populations required 8-16 weeks of daily use. Acute effects in healthy adults (where they occurred) were at single doses of approximately 1.8g.

For healthy adult users seeking cognitive support, the MCI trial data suggests the mechanism requires sustained use rather than single-dose testing. The Menon 2025 systematic review confirmed the safety profile across the existing evidence base, finding no serious adverse events in the reviewed trials at the doses studied.^[6]

The Bottom Line

Lion's mane's strongest cognitive evidence comes from three RCTs in MCI and early AD patients (Mori 2009, Saitsu 2019, Li 2020) showing consistent improvement over 8-16 weeks. The critical honest finding: scores regressed within 4 weeks of stopping in Mori's trial, confirming the effects require continued supplementation. In healthy young adults, Docherty 2023 found task-specific acute effects; Surendran 2025 found no significant global improvement from acute dosing. Cha 2024's systematic review concluded benefits are most reliable in cognitively impaired populations. The mechanism is NGF/BDNF-driven hippocampal neuroplasticity, which explains both the weeks-long timeline and the regression on cessation.

Frequently Asked Questions

Yes, in people with mild cognitive impairment. Three RCTs (Mori 2009, Saitsu 2019, Li 2020) showed consistent cognitive improvement in MCI and early Alzheimer's patients over 8-16 weeks. In healthy young adults, the evidence shows task-specific effects (Docherty 2023) but not global cognitive improvement in all measures (Surendran 2025 acute dose null result). Cha et al.'s 2024 systematic review concluded that benefits are most reliable in cognitively impaired populations.

Lion's mane stimulates nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) production, promoting hippocampal neurogenesis (new neuron growth in the memory center of the brain). Over weeks of supplementation, this supports new neural connection formation and neuron survival. The cognitive improvements seen in clinical trials reflect these structural changes accumulating over 8-16 weeks of use.

For people with mild cognitive impairment: yes, based on multiple double-blind placebo-controlled trials. For healthy adults with normal memory: the evidence is more limited and task-specific. Mori et al.'s 2009 trial is a well-designed randomized controlled study showing significant improvement on cognitive scales in MCI patients. This meets the standard definition of scientific proof for that population; the same strength of evidence does not yet exist for healthy adults.

The Mori 2009 trial used approximately 750mg daily of dried mushroom equivalent; Docherty 2023 used 1.8g of standardized extract. Most research sits between 500mg and 3g daily. Dose alone is insufficient guidance because formulation matters: erinacine-enriched mycelium, fruiting body extract, and whole mushroom powder deliver different compound profiles at the same nominal dose. The most important variable alongside dose is duration: the mechanism requires weeks to produce detectable cognitive effects.

The evidence suggests it slows or partially reverses cognitive decline in MCI and early AD patients with ongoing use, not that it provides permanent correction. Mori 2009 found scores improved significantly over 16 weeks and began declining again within 4 weeks of stopping. This is consistent with the mechanism: lion's mane supports hippocampal neuroplasticity that requires continuous NGF/BDNF stimulation to maintain. Reversal implies permanent correction; the evidence shows managed, ongoing improvement that depends on continued supplementation.

Sources & References

1RTHM-00165·Mori, Koichiro et al. (2009). “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial..” Phytotherapy research : PTR.Study breakdown →PubMed →↩
2RTHM-00585·Saitsu, Yuusuke et al. (2019). “Improvement of cognitive functions by oral intake of Hericium erinaceus..” Biomedical research (Tokyo.Study breakdown →PubMed →↩
3RTHM-00821·Docherty, Sarah et al. (2023). “The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study..” Nutrients.Study breakdown →PubMed →↩
4RTHM-00631·Li, I-Chen et al. (2020). “Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study..” Frontiers in aging neuroscience.Study breakdown →PubMed →↩
5RTHM-00868·Cha, Sara et al. (2024). “A review of the effects of mushrooms on mood and neurocognitive health across the lifespan..” Neuroscience and biobehavioral reviews.Study breakdown →PubMed →↩
6RTHM-00943·Menon, Arya et al. (2025). “Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review..” Frontiers in nutrition.Study breakdown →PubMed →↩
7RTHM-00952·Surendran, Geyan et al. (2025). “Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study..” Frontiers in nutrition.Study breakdown →PubMed →↩
8RTHM-01662·Brandalise, Federico et al. (2023). “Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond, How Far from the Shoreline?.” Journal of fungi (Basel.Study breakdown →PubMed →↩